DE3931585A1
(de)
*
|
1989-09-22 |
1991-04-04 |
Merck Patent Gmbh |
Aminosaeurederivate
|
WO1993006127A1
(en)
*
|
1991-09-17 |
1993-04-01 |
Warner-Lambert Company |
Novel amino acid prodrug renin inhibitors
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
AU3084802A
(en)
|
2000-12-14 |
2002-06-24 |
Brigham & Womens Hospital |
Inflammatory markers as tools in the detection and prevention of diabetes mellitus and as tools to aid in the selection of agents to be used for the prevention and treatment of diabetes
|
ES2375181T3
(es)
|
2002-05-09 |
2012-02-27 |
The Brigham And Women's Hospital, Inc. |
1l 1rl-1 como un marcador de enfermedades cardiovasculares.
|
US7273616B2
(en)
*
|
2002-05-10 |
2007-09-25 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
|
CA2536173A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
AU2004270162B2
(en)
*
|
2003-08-28 |
2010-05-13 |
Nicox S.A. |
Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
|
EP3081214A3
(en)
|
2003-08-29 |
2016-11-16 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of cellular necrosis
|
ATE546734T1
(de)
|
2003-12-05 |
2012-03-15 |
Cleveland Clinic Foundation |
Risikomarker für eine herzkreislaufkrankheit
|
AU2005207037A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
WO2006042192A2
(en)
|
2004-10-06 |
2006-04-20 |
The Brigham And Womens's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
US20080275093A1
(en)
*
|
2004-11-15 |
2008-11-06 |
Nitromed, Inc. |
Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
EP1846380A4
(en)
*
|
2005-01-21 |
2010-02-17 |
Nicox Sa |
HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME
|
EP1848424B1
(en)
*
|
2005-01-31 |
2017-04-05 |
Mylan Laboratories, Inc |
Pharmaceutical composition comprising hydroxylated nebivolol
|
WO2007086884A2
(en)
*
|
2005-02-16 |
2007-08-02 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
CA2597463A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
AU2006223392A1
(en)
*
|
2005-03-09 |
2006-09-21 |
Nicox S.A. |
Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
|
AP2896A
(en)
|
2005-05-31 |
2014-05-31 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
EP1915157A4
(en)
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
NICKEL OXYGENIZING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USE PROCESSES
|
EP1942909A4
(en)
*
|
2005-10-04 |
2010-01-06 |
Nitromed Inc |
METHODS OF TREATING RESPIRATORY DISORDERS
|
US8119358B2
(en)
*
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
EP1954685A4
(en)
*
|
2005-11-16 |
2009-11-11 |
Nitromed Inc |
FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
|
US20090053328A1
(en)
*
|
2005-12-20 |
2009-02-26 |
Nitromed, Inc. |
Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use
|
US20080293702A1
(en)
*
|
2005-12-22 |
2008-11-27 |
Nitromed, Inc. |
Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
|
EP2030025A2
(en)
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
WO2008058402A1
(en)
|
2006-11-17 |
2008-05-22 |
Queen's University At Kingston |
Compounds and methods for treating protein folding disorders
|
ES2434215T3
(es)
|
2007-04-18 |
2013-12-16 |
Tethys Bioscience, Inc. |
Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
AU2009322836B2
(en)
|
2008-11-25 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
JP2012511002A
(ja)
|
2008-12-05 |
2012-05-17 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンジオテンシンii受容体アンタゴニストとしてのニトロオキシ誘導体
|
AU2010218224B2
(en)
|
2009-02-26 |
2013-06-27 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
CN103037829A
(zh)
|
2010-02-01 |
2013-04-10 |
儿童医院 |
用于治疗和预防再狭窄的远程缺血调节
|
CA2795053A1
(en)
|
2010-03-31 |
2011-10-06 |
The Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
EP2571351B1
(en)
|
2010-05-21 |
2016-09-14 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
CN103347385A
(zh)
|
2010-10-29 |
2013-10-09 |
默沙东公司 |
二醇二氮烯鎓类杂环衍生物
|
US8933113B2
(en)
|
2011-01-20 |
2015-01-13 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
EP2697203B1
(en)
|
2011-04-13 |
2017-05-24 |
Merck Sharp & Dohme Corporation |
Mineralocorticoid receptor antagonists
|
JP5883501B2
(ja)
|
2011-04-26 |
2016-03-15 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
アルドステロンシンターゼインヒビター
|
WO2012151114A1
(en)
|
2011-05-02 |
2012-11-08 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
EP2773199B1
(en)
|
2011-10-31 |
2019-04-10 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
WO2013066717A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
CA2873214C
(en)
|
2012-05-11 |
2021-02-16 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
AU2013296803B2
(en)
|
2012-08-01 |
2018-03-08 |
Eric Ostertag |
Free flowing, frozen compositions comprising a therapeutic agent
|
US9777002B2
(en)
|
2012-11-29 |
2017-10-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
US9783552B2
(en)
|
2013-12-11 |
2017-10-10 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
EP3079701B1
(en)
|
2013-12-11 |
2021-08-11 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
EP3083573A4
(en)
|
2013-12-18 |
2017-08-02 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
WO2015183938A1
(en)
|
2014-05-29 |
2015-12-03 |
Geneticure Llc |
Improved therapeutic regimen for hypertension
|
WO2016018729A1
(en)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
CN115043945A
(zh)
|
2014-10-31 |
2022-09-13 |
Ngm生物制药有限公司 |
用于治疗代谢病症的组合物和方法
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
WO2016191334A1
(en)
|
2015-05-27 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
US10213429B2
(en)
|
2015-05-28 |
2019-02-26 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
WO2017011279A1
(en)
|
2015-07-13 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2020236690A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
WO2020236688A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
JP2023534704A
(ja)
|
2020-07-22 |
2023-08-10 |
ヤンセン ファーマシューティカ エヌ.ベー. |
第xia因子阻害剤として有用な化合物
|
US11814364B2
(en)
|
2021-03-18 |
2023-11-14 |
Janssen Pharmaceutica Nv |
Pyridine N-oxide derivatives useful as factor XIa inhibitors
|
US11919881B2
(en)
|
2021-03-18 |
2024-03-05 |
Janssen Pharmaceutica Nv |
Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
US11845748B2
(en)
|
2021-03-18 |
2023-12-19 |
Janssen Pharmaceutica Nv |
Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
US11897880B2
(en)
|
2021-04-30 |
2024-02-13 |
Janssen Pharmaceutica Nv |
7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
|
US11958856B2
(en)
|
2021-07-22 |
2024-04-16 |
Janssen Pharmaceutica Nv |
Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
|